LIVE WEBINAR: Wednesday, April 21, 2021, 4:45 PM – 5:45 PM Eastern Time

Dissecting the Decision: Investigator Perspectives on Key Issues in the Management of Common Cancers

13th Annual Oncology Grand Rounds NCPD Webinar Series

Colorectal and Gastroesophageal Cancers

Register for the REPLAY of this event taking place on May 6

Register for this complimentary event with the “Register” button above,
which will take you to our Zoom registration page.

Faculty
Johanna Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Daniel Catenacci, MD
Associate Professor, Department of Medicine
Section of Hematology and Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research
Comprehensive Cancer Center
The University of Chicago Medical Center and Biological Sciences
Chicago, Illinois

Nurse Case Presentations By
Jessica Mitchell, APRN, CNP, MPH
Assistant Professor of Oncology
Mayo Clinic College of Medicine and Science
Rochester, Minnesota

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Lilly and Taiho Oncology Inc.

Wednesday, April 21, 2021
4:45 PM – 5:45 PM Eastern Time
Live NCPD-accredited webinar

Topics to Be Discussed

  • Overview of the incidence and prognosis of colorectal and gastroesophageal cancers; patient signs and symptoms at presentation and diagnostic/staging considerations; key patient- and disease-specific factors affecting patient care
  • Clinical and biologic factors affecting the sequencing of TAS-102 and regorafenib for patients with metastatic colorectal cancer (mCRC); available data with and potential clinical role of TAS-102 in combination with bevacizumab
  • Management of mCRC with BRAF V600E mutations; activity and tolerability of BRAF/EGFR-inhibitor combination therapy; spectrum and optimal management of side effects
  • Research findings guiding the FDA approvals of nivolumab, pembrolizumab and nivolumab/ipilimumab for patients with microsatellite instability-high/mismatch repair-deficient mCRC; patient selection for anti-PD-1 monotherapy versus combined anti-PD-1/anti-CTLA-4 therapy
  • Patient and clinical factors affecting the selection of therapy for HER2-negative metastatic gastric or gastroesophageal junction (GEJ) cancer in the first-line setting; current role and optimal integration of immune checkpoint inhibitors alone or in combination with chemotherapy
  • Sequencing of available systemic therapy options for patients with metastatic gastric cancer who have experienced disease progression on first-line therapy; use of biomarkers and clinical factors to select treatment
  • Management of relapsed HER2-positive metastatic gastric/GEJ cancer: Effectiveness and incorporation of trastuzumab deruxtecan, pembrolizumab for patients with PD-L1 CPS ≥1, and common toxicities and side-effect mitigation
  • Newly approved agents: Mechanism of action, efficacy, and incidence, type and management of associated adverse events

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of colorectal and gastroesophageal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Educate patients with metastatic colorectal cancer (mCRC) regarding the importance of biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals of treatment in the selection and sequencing of therapy.
  • Appreciate published research data documenting the efficacy of combined BRAF and EGFR inhibition for patients with relapsed/refractory mCRC and a BRAF V600E mutation, and understand how this regimen is being optimally incorporated into clinical care.
  • Evaluate available data with and the FDA approvals of nivolumab, pembrolizumab and the combination of nivolumab/ipilimumab for microsatellite instability-high or mismatch repair-deficient mCRC, and identify patients for whom anti-PD-1-based therapy is appropriate.
  • Recognize available data with anti-HER2 therapy for patients with HER2-positive mCRC, and consider the current and future role of various investigational approaches.
  • Assess the relevance of HER2 status, PD-L1 combined positive score, clinical factors and patient preferences in order to develop strategies to counsel individuals with locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer regarding personalized treatment recommendations.
  • Describe published research data with immune checkpoint inhibitors alone or in combination with chemotherapy in the management of gastric/GEJ cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
  • Recall the biologic rationale for and available data with trastuzumab deruxtecan for patients with previously treated HER2-overexpressing gastric/GEJ cancer, and discern the current and potential clinical applicability of this therapeutic strategy.
  • Consider recently presented clinical trial findings with anti-PD-1 antibodies as adjuvant therapy or as a component of first-line treatment for patients with esophageal cancer, and assess the potential role of these strategies.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for colorectal and gastroesophageal cancers, and refer appropriate patients for trial participation.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2021/GICancers/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr BendellConsulting Agreements (to Institution): Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, a wholly owned subsidiary of Eli Lilly and Company, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Fusion Pharmaceuticals, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Prelude Therapeutics, Relay Therapeutics, Repertoire Immune Medicines, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc; Contracted Research (to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, a wholly owned subsidiary of Eli Lilly and Company, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bellicum Pharmaceuticals Inc, Bicycle Therapeutics, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, CALGB, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Cyteir Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, Hutchison MediPharma, IGM Biosciences Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma Inc, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Morphotek Inc, Nektar, NeoImmuneTech, NGM Biopharmaceuticals, Novartis, NovoCure Inc, Numab, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, OncXerna Therapeutics Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, PureTech Health, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Repare Therapeutics, Revolution Medicines, Rgenix, Sanofi Genzyme, Scholar Rock, Seagen Inc, Shattuck Labs, Sierra Oncology, Sumitomo Dainippon Pharma Oncology Inc, Stemcentrx, SynDevRx Inc, Synthorx, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Transcenta, Treadwell Therapeutics, Tyrogenex, Unum Therapeutics, Vyriad, Zymeworks. Dr CatenacciAdvisory Committee: Astellas, Merck, Seagen Inc, Tempus; Consulting Agreements: Amgen Inc, Archer Pharmaceuticals, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gritstone Oncology, Guardant Health, Lilly, Merck, Natera Inc, Pieris Pharmaceuticals Inc, QED Therapeutics, Seagen Inc, Taiho Oncology Inc, Tempus, Zymeworks; Contracted Research: Amgen Inc, Genentech, a member of the Roche Group; Data and Safety Board: Genentech, a member of the Roche Group, Merck Serono; Speakers Bureau: Genentech, a member of the Roche Group, Guardant Health, Lilly, Merck, Tempus.

CONTRIBUTING NURSESMs Mitchell had no relevant conflicts of interest to disclose.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Lilly and Taiho Oncology Inc.